Heron Therapeutics designates Ira Duarte as principal accounting officer, replacing Lisa Peraza

HERON THERAPEUTICS, INC. /DE/

Ira Duarte appointed principal accounting officer effective March 29, 2024, succeeding Lisa Peraza.
Lisa Peraza will remain as chief accounting officer until her employment ends on the effective date.
No additional compensation or adjustments for Duarte in connection with the new role.
Duarte already serves as EVP and CFO; no family relationships or related party transactions with the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Ira Duarte

principal accounting officer

HRTX · HERON THERAPEUTICS, INC. /DE/

Effective: 2024-03-29
Filed: March 21, 2024, 7:59 PM ET

On March 18, 2024, Ira Duarte was designated as Heron Therapeutics, Inc.’s principal accounting officer, replacing Lisa Peraza, the Company’s current Chief Accounting Officer and principal accounting officer, effective March 29, 2024 (the “Effective Date”).

Departed

Lisa Peraza

Chief Accounting Officer

HRTX · HERON THERAPEUTICS, INC. /DE/

Effective: 2024-03-29
Successor: Ira Duarte
Filed: March 21, 2024, 7:59 PM ET

Ms. Peraza will continue to serve in her current position until her employment with the Company ends on the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ira Duarte changed role as principal accounting officer at HERON THERAPEUTICS, INC. /DE/.

Action: designated
Role: principal accounting officer

Exact text from the filing

On March 18, 2024, Ira Duarte was designated as Heron Therapeutics, Inc.’s principal accounting officer, replacing Lisa Peraza, the Company’s current Chief Accounting Officer and principal accounting officer, effective March 29, 2024 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lisa Peraza departed as Chief Accounting Officer at HERON THERAPEUTICS, INC. /DE/.

Action: ends
Role: Chief Accounting Officer

Exact text from the filing

Ms. Peraza will continue to serve in her current position until her employment with the Company ends on the Effective Date.

View on SEC.gov

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-24-073897

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.